Answers are grounded in this paper and cite their sources.
Although ISA has been approved for treatment of invasive Aspergillus and mucormycosis, we observed an increased rate of bIFI, notably IPA, using ISA for primary prophylaxis. These results support the need for further study to determine the role of ISA as primary prophylaxis.
No takes yet. Share an insight, caveat, or question.
Fontana et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: